Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Buys 79,259 Shares of Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc acquired 79,259 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $13.99 per share, for a total transaction of $1,108,833.41. Following the completion of the transaction, the insider directly owned 909,843 shares of the company’s stock, valued at $12,728,703.57. This trade represents a 9.54% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, May 15th, Adar1 Capital Management, Llc acquired 300 shares of Rallybio stock. The stock was bought at an average cost of $13.90 per share, for a total transaction of $4,170.00.
• On Tuesday, May 12th, Adar1 Capital Management, Llc acquired 800 shares of Rallybio stock. The stock was bought at an average cost of $13.83 per share, for a total transaction of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc bought 50,000 shares of Rallybio stock. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The shares were acquired at an average cost of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Stock Performance

Shares of NASDAQ RLYB traded up $0.09 during midday trading on Friday, reaching $14.30. 53,608 shares of the company’s stock were exchanged, compared to its average volume of 636,356. Rallybio Corporation has a 52-week low of $2.16 and a 52-week high of $15.31. The stock has a market capitalization of $75.79 million, a PE ratio of -5.59 and a beta of -1.10. The business’s fifty day moving average price is $9.84 and its two-hundred day moving average price is $7.05.

Rallybio (NASDAQ:RLYB) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RLYB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. Wall Street Zen raised shares of Rallybio to a “hold” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Trading of Rallybio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. Citadel Advisors LLC increased its holdings in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Geode Capital Management LLC increased its holdings in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Susquehanna International Group LLP increased its holdings in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. 90.34% of the stock is owned by institutional investors.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.